Latest news from Amphista

Amphista Therapeutics presents new preclinical data showing the potential of its BRD9 Targeted Glue™, AMX-883, to transform the treatment paradigm for acute myeloid leukaemia

Amphista Therapeutics announces AMX-883 data to be presented at the ASH Annual Meeting and Exposition and provides a business progress update

Amphista Therapeutics to showcase how its Targeted Glue™ technology is expanding the diversity of TPD medicines at the 8th Annual TPD & Induced Proximity Summit 2025

Amphista Therapeutics’ successful degradation of a key cancer target, BRD9, via a novel mechanism with DCAF16 E3 ligase published in Nature Communications

Amphista Therapeutics announces three key strategic leadership appointments to drive transition of its Targeted Glue™ protein degraders into clinical development

Amphista Therapeutics nominates AMX-883, an orally available Targeted Glue™ degrader of BRD9, as its first clinical development candidate for the treatment of acute myeloid leukaemia